Pfizer (US) has invested USD 27 million in increasing production capacity in Itapevi, Brazil. This investment will increase the US firm's production capacity in Itapevi from 20 million units per year to 48 million units, through the improvement of its technology and processes, with full capacity expected to be reached in 2016. Additionally, the US company is also planning to add approximately 20 innovative medicines to its portfolio produced in Brazil.